Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults.
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Type 1 or 2 Diabetes Mellitus treated with diet or medication
Clinically or microbiologically documented foot infection below the knee
Osteomyelitic bone must be removed within 48 hours of study entry
Uncomplicated skin infections
Infected burn wounds
Wounds with gangrene that cannot be removed with debridement
Infections of prosthetic materials
Foreign materials that can not be removed by surgical debridement
Patients with another antibiotic 3 days prior to enrollment without evidence of treatment failure and presence of a positive culture
Insufficient blood flow to the limb requiring a revascularization procedure